This Web Site is committed to the memory of Janis Morrow.
Cirrhosis
2008
Back to
information Index
Dec - Nov
AASLD: Mortality Risk in HCV-Positive
Transplant Patients Similar Regardless of Donor Status
Higher SVR GENO
2 vs 3 Advanced Fibrosis-
Cirrhosis
Low
SVR Tx-Naive Advanced-
Fibrosis Cirrhosis
|
Pegasys Maintenance in HALT-C
http://www.hcvadvocate.org/news/newsRev/2008/HJR-5.12.html
Nearly half of all people treated for
chronic hepatitis C do not achieve a cure,
and researchers are studying whether
long-term low-dose pegylated interferon
maintenance therapy can slow or prevent
liver disease progression. Results from the
largest such study, HALT-C, were published
in the December 4, 2008 New England
Journal of Medicine. A. DiBisceglie and
colleagues initially treated chronic
hepatitis C patients with advanced liver
disease using standard-of-care 180 mcg/week
pegylated interferon alfa-2a (Pegasys) plus
weight-adjusted ribavirin. A total of 1,050
nonresponders and relapsers were then
randomly assigned to receive either low-dose
(90 mcg/week) Pegasys monotherapy or no
ongoing therapy.
After 3.5 years,
ALT levels, HCV viral load, and histological
necroinflammatory scores decreased
significantly in the treated patients. But
there were no significant differences in
rates of hepatocellular carcinoma, hepatic
decompensation, fibrosis score increase of
two or more points, or death (34.1% for the
combined endpoint in the treatment arm vs.
33.8% in the untreated arm). Eight patients
taking Pegasys maintenance therapy died,
compared with two untreated participants.
Percentages of patients with at least one
serious adverse event were 38.6% and 31.8%,
respectively (not quite statistically
significant). The researchers concluded
that, “Long-term therapy with peginterferon
did not reduce the rate of disease
progression in patients with chronic
hepatitis C and advanced fibrosis, with or
without cirrhosis, who had not had a
response to initial treatment with
peginterferon and ribavirin." Speaking to
the media, Dr. DiBisceglie added, “To the
extent there are still patients out there
who are on this form of maintenance therapy,
there is a real take-home message: It should
be stopped.”
The HALT-C findings
were surprising to many because reduced ALT
and histological necroinflammatory activity
– as seen in an interim analysis – were
presumed to be markers for improved liver
health. Contrary to these results, a smaller
German study presented by S. Kaiser at the
recent AASLD Liver Meeting (abstract 117)
found that low-dose monotherapy with 0.5
mcg/kg/week pegylated interferon alfa-2b (PegIntron)
for three or six years led to a "significant
and persistent" decrease in fibrosis. While
the debate over pegylated interferon
maintenance continues, nonresponders
considering this approach should be aware
that directly targeted "STAT-C" drugs,
expected to become available in a couple
years, may offer a better option. |
|
|
Hepatitis C treatment reduces the virus but liver
damage continues
Treating patients who have chronic hepatitis C and advanced liver
disease with long-term pegylated interferon significantly decreased
their liver enzymes, viral levels and liver inflammation, but the
treatment did not slow or prevent the progression of serious liver
disease, a study finds.
These
findings come from the clinical trial, Hepatitis C Antiviral
Long-Term Treatment Against Cirrhosis (HALT-C) and are reported in
the Dec. 4 issue of the New England Journal of Medicine. HALT-C was
funded by the National Institutes of Health (NIH) with additional
support from Hoffmann-La Roche Inc.
"The
results from HALT- C show without question that maintenance therapy
with peginterferon does not prevent progression of liver disease
among patients who have failed prior treatments," said James
Everhart, M.D., project scientist for HALT-C in the Division of
Digestive Diseases and Nutrition, National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), the principal sponsor of
HALT-C at NIH. "These findings heighten the incentive to develop
more effective drugs for patients with severe liver disease due to
hepatitis C."
According to a press release issued by EurekAlert, Peginterferon
therapy for up to 48 weeks is standard for chronic hepatitis C. But
patients who do not have a sustained response to initial therapy
have been given the drug over a longer time based on studies showing
that this approach suppresses viral and enzyme levels, even if the
virus is not completely eliminated. However, it was not known if
long-term therapy would improve important clinical outcomes such as
liver damage and death.
HALT-C, a randomized multicenter trial of 1,050 patients with
chronic hepatitis C who had failed prior treatment to eradicate the
infection, tested whether long-term treatment with peginterferon
alfa-2a would reduce the development of cirrhosis, liver cancer, or
liver failure. The 517 patients randomized to the treatment arm
received 90 micrograms of peginterferon in weekly injections for 3.5
years. The 533 patients in the control arm underwent the same
follow-up and care as the treated patients including liver biopsies,
quarterly clinic visits and blood tests. All patients had advanced
liver fibrosis, a gradual scarring of the liver that puts patients
at risk for progressive liver disease and liver failure.
The
outcomes studied in HALT-C were death, liver cancer, or liver
failure, and for those who did not have cirrhosis initially, the
development of cirrhosis. At the end of the study, 34.1 percent of
the treated group and 33.8 percent of the control group had
experienced at least one outcome. Patients in the treated group had
significantly lower blood levels of the hepatitis C virus and
improvement in liver inflammation. However, there was no major
difference in rates of any of the primary outcomes between the
groups.
Among
treated patients, 17 percent stopped peginterferon after 18 months
and 30 percent stopped the drug after two years. Infections,
musculoskeletal or digestive problems were the most common reasons
for stopping the drug.
According to HALT-C study chair and principal investigator Adrian M.
Di Bisceglie, M.D., professor of internal medicine at Saint Louis
University School of Medicine in Missouri, looking into how
maintenance therapy works in non-responders is an important step.
"Patients should not receive interferon as maintenance therapy for
chronic hepatitis C. However, we can build on what was learned in
HALT-C to identify better treatments that may delay or prevent liver
damage in patients with advanced disease," he said.
The
hepatitis C virus infects more than 100 million persons worldwide
and as many as 4 million in the United States. Hepatitis C ranks
with alcohol abuse as the most common cause of chronic liver disease
and leads to about 1,000 liver transplants in the United States each
year. The best current antiviral therapy of pegylated interferon
given by injection in combination with oral ribavirin for about 6
months to a year eliminates the virus in about 50 percent of
infected patients.
http://www.hindu.com/thehindu/holnus/099200812101522.htm
HealthWise:
What We Eat
|
HealthWise:
What We Eat
Lucinda Porter, RN
The U.S. National Day of
Eating, affectionately known as
Thanksgiving, is around the corner. Between
leftovers and football snacks, several days
are spent consuming food. This is followed
by more holidays. Food is everywhere – at
work, the bank, even the health club.
Champion eaters say that
Thanksgiving is amateur day. They don’t
need a holiday to celebrate food. If you
are an amateur, you will go on a diet in
January. A pro extends the eating
opportunity through Super Bowl Sunday. The
elite keep going through Valentine’s Day.
I am a champion eater.
However, as much as I love to eat, nothing
tastes as good as feeling good feels. Over
the years I have learned to balance my
desire for food with my desire to be
healthy. Awareness is the cornerstone.
This means thinking about what I eat before
I eat it, developing a practice, maintaining
a commitment and getting back on track when
I fall off.
Food is the focus of this
month’s column. What does food have to do
with chronic hepatitis C virus (HCV)
infection? Everything. What we eat can
lead to weight problems, fatty liver and
type 2 diabetes. These conditions are
associated with a poorer HCV prognosis. HCV
treatment is less likely to be effective for
those who are overweight or obese.
Most of us will die with
HCV rather than of it. It makes sense to
stack the deck in our favor by making the
healthiest choices possible. Changes in the
diet may help or eliminate fatty liver,
adult-onset diabetes, and high cholesterol.
Healthy food choices may help us avoid a
host of diet and weight-related diseases.
Good nutrition relies
on knowing:
• What to eat
• How much to eat
• What is in your food
• Putting this knowledge into practice
Ask experts what to eat
and you will get more responses than there
were candidates running for the presidential
primaries. In his book, In Defense of
Food, Michael Pollan suggests, “Eat
food. Not too much. Mostly plants.” By
“eat food,”Pollan advises eating
food that hasn’t been processed. I would
add: whenever you can, eat food that is
grown locally and make it colorful. This
maximizes your chances of getting adequate
nutrition.
Here are resources to
help you choose a nutrition plan to suit
you:
• Harvard School of Public
Health
www.hsph.harvard.edu/
nutritionsource/index.html
• Oldways
www.oldwayspt.org/
med_pyramid.html
• United States Department
of Agriculture (USDA)
www.mypyramid.gov
How much to eat is
tailored to each person. Our age, size and
activity level influence the amount of food
we should consume. Use a food plan as a
guideline. Never use restaurant portions as
an authority on how much to eat or you will
supersize yourself into a triple by-pass.
For me, how much to eat is a simple
equation. As long as I am maintaining my
weight, I am in the correct range. If I
gain weight it is because I am eating too
much. If I lose weight it is because I have
leukemia or a tape worm because it certainly
won’t be because I ate too little.
How much we eat is as
important as what we eat. For instance,
most of us like ice cream. There is nothing
wrong with an occasional indulgence.
However, few realize that a serving of ice
cream is about the size of ½ of a baseball.
A serving of meat is the size of a deck of
cards. Eat a pound of steak and you consume
more than 5 servings.
Here are some
resources to help you gauge your nutritional
needs:
• Aim for a Healthy Weight
www.nhlbi.nih.gov/health/public/heart
/obesity/lose_wt/index.htm
This website is sponsored by the National
Heart Lung and Blood Institute and has
excellent tools.
• USDA’s nutrition
information
www.nutrition.gov
•
www.caloriecontrol.org This
website is free of advertising and has
useful tools. Don’t be fooled by the “.org”
– this is funded by the diet food industry.
•
www.caloriesperhour.com – Another
commercial website that provides useful
tools.
Knowing what is in food is
not always straight-forward. It is easy
when the food comes from the produce section
or the bulk bins at the organic grocery
store. When it comes in a container, then
there is a food label. Next month’s column
will be devoted to reading labels. For now,
the key point is to pay attention to portion
size. Read the label for how many servings
are in a container. For instance, those tiny
cartons of ice cream look as if they are the
perfect size for one person. Unfortunately,
they usually hold 4 to 6 servings.
Putting this knowledge
into use is like any new skill. It gets
easier with practice. Once I knew what I
needed and how to maintain a healthy diet,
it became routine. The challenges are the
psychological and social aspects of eating.
Although we eat to live, we also eat to
celebrate, to mourn, for comfort and for
pleasure. Sometimes this can get out of
hand, especially during holidays.
When I get off track, I
try to get back on as soon as possible. A
long time ago, I gave up food-related guilt
and remorse. This helps me settle back into
my routine more quickly. Guilt and remorse
made the situation worse.
There are some who try and
no matter how hard, they cannot consistently
master a plan of healthy eating. If this is
true for you, there is help. Talk to your
medical provider. Check out resources such
as Overeaters Anonymous or Food
Addicts Anonymous. There are also
for-profit programs that may be right for
you.
This is easier said than
done. For years, I weighed more than I
wanted. I tried to lose weight and keep it
off, but it was not until I underwent HCV
treatment that I was able to drop to a more
comfortable range. The reason I didn’t
regain the weight was because of HCV
patients. I had seen them lose weight
during treatment and then regain it back. I
vowed to keep it off – to live the words I
speak.
Having HCV bestows an
opportunity to eat responsibly. It’s an
excuse to put down the fork and pick up the
walking shoes. It’s a reason to celebrate
life by not overeating rather than
over-indulging. This Thanksgiving, may you
be blessed with health and a full heart
without a bulging belly.
|
|
|
Oct-Sept
Rifaximin Demonstrates Highly
Statistically Significant Results In Prevention Of Hepatic
Encephalopathy In Pivotal Phase 3 Study
An Effective Strategy For Inhibition
Of Cirrhosis
A Novel Therapy For Bleeding Gastric
Varices
New Insights Into The Pathogenic
Mechanisms Of Liver Cirrhosis With Ascites
New Hope For Patients With Advanced
Liver Disease
In Liver Disease Patients Normal ALT
Levels May Mask Advanced Fibrosis
Brain Fog Busters
Silymarin Improves Quality of Life During
Hepatitis C Treatment
You can
visit our forum
as a Guest . If you wish to join
our site in order to communicate with us please
click here
By joining our
forum you will also be able to enter our chat room and post messages.
Video on our Forum :
Treatment Cirrhosis-Tp- SVR
AUG
Antiviral Treatment for Cirrhotic Patients
Obesity and Diabetes Predict Liver Disease Progression
New Insights Into The Pathogenic
Mechanisms Of Liver Cirrhosis With Ascites
Liver damage in hepatitis C patients could be treated
with warfarin, says study
Compensated cirrhosis
July-June
Selected Hepatitis C Patients with Decompensated
Cirrhosis Can Benefit from Interferon-based Therapy prior to Liver
Transplantation
Liver Damage In Hepatitis C Patients
Could Be Treated With Warfarin, Says Study
Diabetic Patients With Advanced Hepatitis C Have
Double The Risk Of Liver Cancer
Elevated Liver Enzymes Linked to Development of
Diabetes
Liver Disease Score Predicts Outcome of Variceal
Hemorrhage
Alcohol Abuse & Dependence Has Big Impact on Cirrhosis
in HIV/HCV Coinfection
(06-01-08)
May
DDW:
Effects of Eltrombopag On Thrombopietin Levels During
Antiviral Therapy in HCV Patients with Cirrhosis
- (05/21/08)
EASL:
Regression of Cirrhosis Occurs & Prevents Death/Events
- (05/16/08)
EASL:
SVR Can Prevent HCC & Other Complications
-
EASL:
SVR Reversed Cirrhosis in 21%
- (05/16/08)
HALT-C Study Design Flawed
-
Study shows positive findings in treating patients
with advanced hepatitis C -
The role of nutrition in hepatic encephalopathy
MR Imaging of Hepatocellular Carcinoma in the
Cirrhotic Liver: Challenges and Controversies
April
HALT-C Study Design Flawed
-
Study shows positive findings in treating patients
with advanced hepatitis C -
Pegylated Interferon Maintenance Demonstrates Benefits
for Hepatitis C Patients with Portal Hypertension
Combination Therapy Improves Survival Time for
Patients with Advanced Liver Cancer
Complications of Cirrhosis -- Clinical
Insights and Implications for Practice
Osteoporosis and Fractures Missing the Bridge? Commentary
-
Two Genetic Variants Found to be Associated with Increased Risk for
Osteoporosis and Fracture -
Safety, tolerability, and efficacy of pegylated-interferon
alfa-2a plus ribavirin in hcv-related
decompensated cirrhotics.
Ray of hope for cirrhosis
Bone disorders in chronic liver disease
Man-made molecules reverse liver cirrhosis in rats
Liver Failure Treatments and Cirrhosis of the liver
CIRRHOSIS IN CHRONIC HEPATITIS C INFECTION
Risk Of Hepatitis C-Related Liver Damage
Increased By Regular Marijuana Use
March-February
Pegylated Interferon plus Ribavirin for Patients with
HCV-related Liver Cirrhosis
Patients With Cirrhosis And Gene
Variation May Have Elevated Risk Of Liver Tumor
Attention: Extra-Hepatic
Manifestation Of Hepatitis C Virus Infection
Increased Oxidative Stress In
Decompensated Cirrhotic Patients
Improved 3-variable model to identify
cirrhosis
New Upper Limit Defined for Normal ALT in Adolescent
Males
-
Cure
for Cirrhosis?
Muscular exercise can cause highly
pathological liver function tests in healthy men
Patients at Risk for Liver Cancer Should Be
Screened With Ultrasound: Presented at ASCO-GI
In Chronic Hepatitis C Silymarin Does Not
Affect Virus Activity Or ALT Levels
Jan 2008
Hepatitis C Virus Affects Many Organs And
Tissues, Not Just Liver
A Liver Disease Breakthrough
Herbal product use by persons enrolled in the
hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
Progressing from Cirrhosis to Liver Cancer May
be Genetic
Gene Variation May Elevate Risk Of Liver Tumor In
Patients With Cirrhosis
Research Offers Promise for Cirrhosis Treatment
Ursodiol Lowers Liver Enzymes in HCV Study
Interferon Maintenance Therapy and Liver
Disease Progression
CIRRHOSIS IN CHRONIC HEPATITIS C INFECTION
2009 Research
2008 Research
2007 Research
2006 Research
2005 Research
2004-2001 Research Archives